Stay updated with breaking news from Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Press Release ENHERTU® Approved in the U.S. as First Tumor Agnostic HER2 Directed Therapy for Previously Treated Patients with Metastatic HER2...
TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--Apr 5, 2024--
Immunocore to present at upcoming investor conferences Immunocore Holdings plc , a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to...
Corporate Presentation April 2024 www.nucana.com Disclaimer ...
One of the building blocks for newly launched Clasp Therapeutics Corp. is making the right patient choices for treatment. If those who receive the company’s therapy are correctly identified, CEO Robert Ross told BioWorld, it will have a profound effect on outcomes. The missing link in cancer treatment, Ross added, was how to identify a patient, something he said Clasp is able to do.